News/ News/ Oncology BMS sets up Roche, Pfizer rivalry with Turning Point takeover Phil Taylor Bristol-Myers Squibb, M&A, novel targeted cancer treatments, Oncology, Turning Point Therapeutics 0 Comment Bristol-Myers Squibb’s all-cash offer for Turning Point Therapeutics – which values the biotech at $4.1 billion – bolsters Share X BMS sets up Roche, Pfizer rivalry with Turning Point takeover https://pharmaphorum.com/news/bms-sets-up-roche-pfizer-rivalry-with-turning-point-takeover/